ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $37M | $-21M | $-26M | $-24M | -91.1% | 17.8% | 35.0% |
| 2024 | $31M | $-16M | $-19M | $-9M | -74.5% | 31.0% | -14.4% |
| 2023 | $24M | $-21M | $-22M | $-15M | -104.3% | 16.6% | 34.4% |
| 2022 | $21M | $-16M | $-16M | $-17M | -44.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 20.55 | 23.96 | 31.39 | 36.97 |
| Operating Revenue | - | 20.55 | 23.96 | 31.39 | 36.97 |
| Cost Of Revenue | - | 7.02 | 10.34 | 12.27 | 14.28 |
| Gross Profit | - | 13.53 | 13.61 | 19.12 | 22.69 |
| Operating Expense | - | 29.86 | 36.06 | 38.86 | 46.86 |
| Research And Development | - | 10.89 | 11.71 | 12.39 | 13.90 |
| Selling General And Administration | - | 18.97 | 24.35 | 26.46 | 32.96 |
| Total Expenses | - | 36.88 | 46.40 | 51.12 | 61.14 |
| Operating Income | - | -16.33 | -22.45 | -19.73 | -24.16 |
| Total Operating Income As Reported | - | -16.33 | -22.45 | -19.73 | -24.16 |
| EBITDA | - | -15.58 | -20.99 | -16.48 | -20.86 |
| Normalized EBITDA | - | -15.58 | -20.99 | -16.48 | -20.86 |
| EBIT | - | -16.35 | -22.45 | -18.38 | -23.10 |
| Interest Income | - | - | 0.39 | 1.39 | 1.21 |
| Interest Expense | 0.97 | 0.08 | - | 0.52 | 2.39 |
| Net Interest Income | - | -0.08 | 0.39 | 0.87 | -1.18 |
| Other Non Operating Income Expenses | - | -0.02 | -0.03 | -0.04 | -0.15 |
| Other Income Expense | - | -0.02 | -0.03 | -0.04 | -0.15 |
| Interest Income Non Operating | - | - | 0.39 | 1.39 | 1.21 |
| Interest Expense Non Operating | 0.97 | 0.08 | - | 0.52 | 2.39 |
| Net Non Operating Interest Income Expense | - | -0.08 | 0.39 | 0.87 | -1.18 |
| Pretax Income | - | -16.43 | -22.09 | -18.90 | -25.48 |
| Tax Provision | - | - | - | 0.01 | 0.06 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income From Continuing And Discontinued Operation | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income From Continuing Operation Net Minority Interest | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income Common Stockholders | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income Including Noncontrolling Interests | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Normalized Income | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Diluted NI Availto Com Stockholders | - | -16.43 | -22.09 | -18.91 | -25.54 |
| Basic Average Shares | 20.73 | 24.18 | 24.61 | 27.03 | - |
| Diluted Average Shares | 20.73 | 24.18 | 24.61 | 27.03 | - |
| Reconciled Depreciation | - | 0.78 | 1.46 | 1.90 | 2.24 |
| Reconciled Cost Of Revenue | - | 7.02 | 10.34 | 12.27 | 14.28 |
| General And Administrative Expense | - | 9.61 | 11.76 | 11.99 | 16.50 |
| Other Gand A | - | 9.61 | 11.76 | 11.99 | 16.50 |
| Selling And Marketing Expense | - | 9.36 | 12.60 | 14.48 | 16.46 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ClearPoint Neuro, Inc.this co. | CLPT | $429M | -16.81 | 15.33 | -91.1% | -21.18 |
| NRC Health | NRC | $445M | 38.37 | 31.82 | 82.9% | 17.20 |
| Myriad Genetics, Inc. | MYGN | $443M | -1.21 | 1.20 | -99.4% | -1.52 |
| Varex Imaging Corporation | VREX | $441M | - | 0.93 | -14.9% | 973.79 |
| Emergent BioSolutions Inc. | EBS | $435M |
| - |
| - |
| - |
| - |
| - |
| - |
| 8.28 |
| 0.83 |
| 10.1% |
| 3.37 |
| Evolus, Inc. | EOLS | $435M | -8.42 | -18.81 | 223.5% | -23.79 |
| Rezolute, Inc. | RZLT | $434M | -5.84 | 2.68 | -45.9% | -4.28 |
| Neurogene Inc. | NGNE | $434M | -4.81 | 1.64 | -34.1% | -3.91 |
| Orthofix Medical Inc. | OFIX | $418M | -4.53 | 0.93 | -20.5% | 51.78 |
| Peer Median | - | -4.53 | 1.07 | -17.7% | 0.93 | |